Autologous Transplantation for Parkinson's Disease Patients:Feasibility and Challenge

• 作者: Qi Zhang Yanlin Wang Yukai Wang Han Liu Huifang Sun Zhuoya Wang Changhe Shi Jing Yang Yuming Xu
• 来源期刊: 神经科学通报（英文版）
• 年，卷（期）: 2021,（7）
• 所属期刊栏目: Research Highlights
• 页码范围: 1085-1086
• 页数: 2页
• 语种: 英文

摘要

Parkinson's Disease(PD),second only to Alzheimer's disease,is a neurodegenerative disease,most commonly occurring in people over the age of 65 years and is mostly caused by loss of dopamine neurons[1].Clinically,motor symptoms such as resting tremor,motor retardation,muscular rigidity,and disturbance of postural balance are the main symptoms,followed by non-motor symptoms such as cognitive impairment,autonomic nervous system dysfunction,depression,and sleep disorder[2].In 2016,＞6.1 million people were affected with PD globally,2.4 times the number in 1990.The large number of affected people,coupled with the high mortality and disability rates,has placed a great burden on society[3].Traditional treatment methods mainly include drugs and surgery and are supplemented by physical therapy.Drugs commonly used include levodopa,dopamine receptor agonists,and monoamine oxidase B inhibitors.Surgical treatment mainly includes deep brain stimulation,focused ultrasound ablation,and placement of a levodopa infusion pump.However,medication or surgical treatment only controls the symptoms and not the progression of the disease[4].New treatments are urgently needed.